Goldman Sachs’s Legend Biotech LEGN Stock Holding History

Goldman Sachs’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-99,400	Closed	-$3.24M	–	6668
2025 Q3	$3.24M	Hold	99,400	–	–	﹤0.01%	4049
2025 Q2	$3.53M	Buy	99,400 +30,000	+43%	+$972K	﹤0.01%	3731
2025 Q1	$2.35M	Hold	69,400	–	–	﹤0.01%	4012
2024 Q4	$2.26M	Sell	69,400 -8,100	-10%	-$336K	﹤0.01%	4173
2024 Q3	$3.78M	Hold	77,500	–	–	﹤0.01%	3605
2024 Q2	$3.43M	Buy	77,500 +47,300	+157%	+$2.18M	﹤0.01%	3501
2024 Q1	$1.69M	Sell	30,200 -18,100	-37%	-$1.09M	﹤0.01%	3980
2023 Q4	$2.91M	Hold	48,300	–	–	﹤0.01%	3625
2023 Q3	$3.24M	Hold	48,300	–	–	﹤0.01%	3368
2023 Q2	$3.33M	Buy	+48,300	New	+$3.16M	﹤0.01%	3456

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FBIL

First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's LEGN Position: Q1 2026 in Review

Goldman Sachs reduced its Legend Biotech (LEGN) stake by 33% in Q1 2026, selling an estimated $13.5M and leaving 1,464,112 shares worth $26.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

Goldman Sachs first reported a position in LEGN in Q4 2020 and has held it in 22 quarters since. The position peaked at $81.1M in Q4 2024. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

Goldman Sachs held 1,464,112 shares of Legend Biotech worth $26.5M as of Q1 2026.
Goldman Sachs sold 710,423 Legend Biotech shares in Q1 2026, an estimated $13.5M.
Legend Biotech made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2166 holding.
Goldman Sachs first reported a position in Legend Biotech in Q4 2020 and has held it in 22 quarters since.
Goldman Sachs's Legend Biotech position peaked at $81.1M in Q4 2024.
190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.